New Science
Volume 18 | Issue 1

Article 13

9-1-2010

Cerebral Palsy: Wayne State University Giving
Hope In a Small (Nano) Way
Julie O'Connor
Wayne State University

Follow this and additional works at: http://digitalcommons.wayne.edu/newscience
Recommended Citation
O'Connor, Julie (2010) "Cerebral Palsy: Wayne State University Giving Hope In a Small (Nano) Way," New Science: Vol. 18: Iss. 1,
Article 13.
Available at: http://digitalcommons.wayne.edu/newscience/vol18/iss1/13

This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in New Science by an
authorized administrator of DigitalCommons@WayneState.

O'Connor: Cerebral Palsy

Cerebral Palsy
by Julie O’Connor
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Scientists in Wayne State’s College of Engineering
and School of Medicine are creating a novel drugcarrying nanodevice for the treatment of cerebral
palsy and other neuroinflammatory diseases.

✼

Published by DigitalCommons@WayneState, 2010

erebral palsy, a neurological disorder that
appears in infancy or early childhood and
permanently affects body movement and muscle
coordination, affects 10,000 newborns yearly
and 800,000 people overall in the U.S. It occurs
as a result of injury to the developing brain that
happens before birth or sometimes during the
first few months or years of life. Conditions such
as prematurity, maternal infections, placental
abnormalities and infections such as meningitis or
encephalitis that occur in the newborn period may
result in brain injury producing cerebral palsy.
A team of researchers from the College of
Engineering, School of Medicine and the National
Institutes of Health’s Perinatal Research Branch
have been collaborating to discover and develop
new nanodevices that will aid in the diagnosis
and treatment of neuroinflammatory diseases and
infections that currently are difficult to target
and treat.
The team led by Rangaramanujam Kannan,
Ph.D., professor of chemical engineering in the
College of Engineering, with collaborators Sujatha
Kannan, M.D., assistant professor of pediatrics in
the School of Medicine and Roberto Romero, M.D.,
chief of the National Institute of Child Health
& Human Development’s Perinatology Research
Branch (PRB) housed at Wayne State University
and the Detroit Medical Center, is developing a
therapeutic approach that will target and treat
neuroinflammation in cerebral palsy. By developing
nanotechnology-based diagnostic and therapeutic
approaches for prevention and treatment of
maternal infections and fetal brain injury, this
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Dr. Diane Chugani, professor of pediatrics and
radiology in the School of Medicine, and the
Positron Emission Tomography Center, has shown
that the presence of neuroinflammation can be
detected at a very early stage using noninvasive
imaging by Positron Emission Tomography.
Clinical translational studies for the detection of
neuroinflammation in at-risk newborns
are ongoing.
“The PRB has established a unit to develop
applications of nanotechnology in perinatal
medicine under the leadership of Dr. R. Kannan
because we are convinced that this approach will
enhance early diagnosis of inflammation in utero
as well as treatment,” commented Dr. Romero.
“Dr. Sujatha Kannan and Dr. R. Kannan have
explored potential mechanisms to prevent and treat
inflammation-induced cerebral palsy. Application
to humans requires new methods for diagnosis and
drug delivery into the amniotic cavity. Such goals
could be accomplished using nanotechnology and,
hence, the partnership between Dr. Kannan and
the Perinatology Research Branch,” Dr. Romero
added. The PRB nanotechnology lab now has
six postdoctoral researchers and two graduate
students with broad research expertise ranging
from chemistry, engineering, neuroscience,
pharmacology, cell biology, animal model
development and imaging.
This novel and high-risk research was initially
funded by the Ralph Wilson Medical Research
Foundation, which provides money for cutting-edge
research in the hope that a breakthrough will be
made to find a cure for devastating conditions such
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About Dr. Rangaramanujam Kannan
Dr. R.M. Kannan received his B.E. in chemical
engineering from the Birla Institute of Technology, and
a Ph.D. in chemical engineering from the California
Institute of Technology. He joined Wayne State
University in 1997.

About Dr. Sujatha Kannan:
Dr. Sujatha Kannan received her M.B.B.S degree
from the Jawaharlal Nehru Institute of Postgraduate
Medical Education and Research (JIPMER, India),
and completed her pediatric residency and critical
care medicine fellowship at WSU/Children’s Hospital
of Michigan. She joined WSU/Children’s Hospital of
Michigan as faculty in 2003.

as cerebral palsy. Rapid advancements in maternalfetal medicine have been enabled by the support
from the PRB. Through the technology being
developed by the Kannan and PRB team, there soon
may be a more effective and safe treatment method
for treating the fetus/newborn for cerebral palsy and
a variety of neurodegenerative conditions that are
difficult to treat.
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team’s promising approach may one day eliminate
or lessen the incidences of cerebral palsy, along
with other neuroinflammatory diseases such as
age-related macular degeneration, Alzheimer’s,
multiple sclerosis, amytrophic lateral sclerosis and
Parkinson’s disease.
These dendrimer-based nanodevices will
target and deliver drugs across the blood-brain
barrier. According to the research team, their
results are the first to show that dendrimers are
able to target the specific site of injury in the
brain in a neuroinflammation model. Using this
nanotherapeutic approach, the targeted drugs are
10 to 100 times more effective than free drugs upon
intravenous administration.
“There is an increasing body of literature, in
addition to evidence from our own research
relating to the disease mechanisms, that suggests
that neuroinflammation plays a key role in the
pathogenesis and evolution of cerebral palsy and
other diseases,” said R. Kannan. “We hope to
develop therapeutic approaches that will target and
treat neuroinflammation resulting in significantly
improved treatment outcomes.”
A wide variety of neurological diseases are very
difficult to treat due to lack of technology able to
target the affected regions in the central nervous
system. “We believe that our novel drug-carrying
nanodevice will offer solutions for treatment of
such conditions by delivering drugs to the specific
target,” R. Kannan added.
Dr. Sujatha Kannan has established an animal
model of inflammation that results in a phenotype
of cerebral palsy. She, in collaboration with
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